NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.
Edinburgh, GB
Size (employees)
21 (est)+5%
NuCana was founded in 2008 and is headquartered in Edinburgh, GB
Report incorrect company information

Key People/Management at NuCana

Hugh Griffith

Hugh Griffith

Ian Abercrombie

Ian Abercrombie

Chief Operating Officer
Chris Wood

Chris Wood

Executive Chairman

NuCana Office Locations

NuCana has an office in Edinburgh and Newton
Edinburgh, GB (HQ)
10 Lochside Place
Newton, US
Riverside Center 275 Grove St
Show all (2)
Report incorrect company information

NuCana Financials and Metrics

NuCana Financials


Net income (FY, 2016)

(6 m)

EBITDA (FY, 2016)

(8.3 m)

EBIT (FY, 2016)

(8.4 m)

Cash (6-Mar-2018)

20 m
GBPFY, 2014FY, 2015FY, 2016

Operating expense total

3.8 m6.9 m9 m


(6.9 m)(8.3 m)


(6.9 m)(8.4 m)

Pre tax profit

(3.7 m)(6.5 m)(8.2 m)
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


117.1 k3.2 k759.2 k1 m6.4 m4.9 m36.4 m29.2 m20 m

Accounts Receivable

42.3 k17.3 k185.8 k385.2 k561.8 k511.7 k639.5 k148.8 k21 k


365.7 k

Current Assets

159.4 k386.1 k945 k1.4 m6.9 m5.4 m37.1 m30.7 m25.8 m
GBPFY, 2014FY, 2015FY, 2016

Net Income

(3.1 m)(5.3 m)(6 m)

Depreciation and Amortization

43.5 k101 k

Accounts Payable

133.1 k220 k

Cash From Operating Activities

(2.6 m)(4.5 m)(9.3 m)
GBPY, 2016

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information